Chiusura precedente | 67,68 |
Aperto | 68,09 |
Denaro | 0,00 x 900 |
Lettera | 0,00 x 1200 |
Min-Max giorno | 68,01 - 68,82 |
Intervallo di 52 settimane | 65,28 - 81,44 |
Volume | |
Media Volume | 8.254.790 |
Capitalizzazione | 143,172B |
Beta (5 anni mensile) | 0,45 |
Rapporto PE (ttm) | 23,07 |
EPS (ttm) | 2,95 |
Prossima data utili | 27 apr 2023 |
Rendimento e dividendo (forward) | 2,28 (3,35%) |
Data ex dividendo | 05 gen 2023 |
Stima target 1A | 81,09 |
LEXINGTON, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- iVexSol Inc., a technology-based lentiviral vector (LVV) contract development and manufacturing organization (CDMO), announced $23.8 million in Series A-3 funding. New investors Bristol Myers Squibb (NYSE: BMY), Charles River Laboratories (NYSE: CRL) and Asahi Kasei Medical, a division of Asahi Kasei (NYSE: AHKSY), join existing investors which include Casdin Capital and BioLife Solutions (Nasdaq: BLFS) to close Series A financing at a total of
– $25 million equity investment from Bristol Myers Squibb at $18.25 per share – – Term loan facility from Hercules Capital provides up to $125 million – – Proceeds extend Kura’s cash runway into 2026, if term loan is fully drawn – SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced a $25 million equity investment from Brist
- Bristol Myers Squibb to receive access to Autolus’ RQR8 safety switch for use in cell therapy programs - - Autolus to receive an upfront payment, with potential for near term option exercise fees and development milestone payments plus royalties - LONDON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that it has entered into an agreement with Bristol M